Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 6, Issue 12, pp. 1511-1523
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 29, 2018
- Revision received July 18, 2018
- Accepted September 14, 2018
- Published first September 21, 2018.
Article Versions
- Previous version (September 21, 2018 - 06:49).
- Previous version (October 5, 2018 - 06:59).
- You are viewing the most recent version of this article.
Copyright & Usage
©2018 American Association for Cancer Research.
Author Information
- Patrick H. Lizotte1,2,
- Ruey-Long Hong3,
- Troy A. Luster1,2,
- Megan E. Cavanaugh1,2,
- Luke J. Taus1,2,
- Stephen Wang1,2,
- Abha Dhaneshwar1,2,
- Naomi Mayman1,2,
- Aaron Yang1,2,
- Meghana Kulkarni1,2,
- Lauren Badalucco1,2,
- Erica Fitzpatrick1,2,
- Hsiang-Fong Kao3,
- Mari Kuraguchi1,2,
- Mark Bittinger1,2,
- Paul T. Kirschmeier1,2,
- Nathanael S. Gray4,5,
- David A. Barbie1,2,6, and
- Pasi A. Jänne1,2,6,*
- 1Belfer Center for Applied Cancer Science, Boston, Massachusetts.
- 2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 3Department of Oncology, National Taiwan University Hospital, Zhongzheng District, Taipei City, Taiwan.
- 4Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 5Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
- 6Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- ↵*Corresponding Author:
Pasi A. Jänne, Dana-Farber Cancer Institute, 450 Brookline Avenue, LC-4114,Boston, MA 02215. Phone: 617-632-6076; Fax: 617-582-7683; E-mail: Pasi_Janne{at}dfci.harvard.edu
December 2018
Volume 6, Issue 12
Volume 6, Issue 12
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Jump to section
Advertisement